An Observational, Multicenter Study on the Safety and Efficacy of Femara(Letrozole) as an Extended Adjuvant Treatment in Breast Cancer Patients Who Completed Adjuvant Tamoxifen or Toremifen Treatment
Phase of Trial: Phase IV
Latest Information Update: 29 Jun 2015
At a glance
- Drugs Letrozole (Primary)
- Indications Breast cancer
- Focus Adverse reactions
- Sponsors Novartis
- 24 Jun 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 13 Mar 2015 Planned End Date changed from 1 Dec 2012 to 1 Apr 2015 as reported by ClinicalTrials.gov record.
- 13 Mar 2015 Planned primary completion date changed from 1 Dec 2011 to 1 Apr 2015 as reported by ClinicalTrials.gov record.